Tag Archives: resTORbio Inc.

Biotech IPO scene shifts into pre-holiday slow gear, but several former IPOs are soaring with analysts saying Buy, Buy, Buy!

IPO Sector: US tech IPOs have mostly vanished in the fourth quarter following disappointments from multiple fast-growing, unprofitable unicorns. Healthcare (55% of 4Q IPOs) and Chinese issuers (24%) have hogged… Read more »

Biotech IPOs rock in 2018. More are storming into the queue.

Steve’s Take: Cutting-edge biotech startups and more established privately-funded but publicly held hopefuls are far and away the winners of the race for deep-pocket investors since New Year’s. I thought… Read more »